MSB Mesoblast Ltd.

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment

Randomized Controlled Phase 3 Trial of Remestemcel-L for Reduced Mortality in COVID-19 Acute Respiratory Distress Syndrome Surpasses 50% Enrollment
EN
13/10/2020

Underlying

MSBMesoblast Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mesoblast Ltd.

 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthc...

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York. Me...

September 15, 2025 1 EN
Free Trial
MSB MESOBLAST LTD.

Mesoblast Ltd: 1 director

A director at Mesoblast Ltd bought 12,899,082 shares at 1.461USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

09/12/25 September 12, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast’s option, following shareholder ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Banner Year for Mesoblast With First FDA Product Approval and Successf...

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil®, the first an...

August 29, 2025 1 EN
 PRESS RELEASE
Free
MSB MESOBLAST LTD.

Mesoblast Financial Results and Corporate Update Webcast

Mesoblast Financial Results and Corporate Update Webcast NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025. The webcast will begin at 6.30pm EDT, Thursday, August 28; 8.30am AEST, Friday, August 29, 2025. It can be accessed via: The archived webcast will be available on the Investor page of the Company’s website: About Mesoblast Mesoblast (the Company) is a ...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch